BiomX director entity sells shares and warrants

BiomX Inc. director and 10% owner Yeganeh Reuven, through Pyu Pyu Capital LLC, converted Series Y Convertible Preferred Stock into Common Stock at a conversion price of $2.00 per share and then sold the resulting shares in private transactions.

Rhea-AI Filing Summary

BiomX Inc. director and 10% owner Yeganeh Reuven, through Pyu Pyu Capital LLC, converted Series Y Convertible Preferred Stock into Common Stock at a conversion price of $2.00 per share and then sold the resulting shares in private transactions.

Pyu Pyu Capital LLC received 450,000 and 530,000 Common shares upon conversion and sold all 980,000 shares at $5.00 per share in private deals. It also sold 5,000,000 Common Stock Purchase Warrants in private transactions at prices between $4.76 and $5.24 per warrant share, leaving no Common Stock or warrants reported as held after these transactions.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 9 txns

Insider Yeganeh Reuven

Role Director, 10% Owner

Sold 5,980,000 shs ($29.97M)

Approx. gross sale proceeds $4.90M

Approx. exercise cost $4K

Type	Security	Shares	Price	Value
Conversion	Series Y Convertible Preferred Stock	1,060	$0.00	$0.00
Conversion	Common Stock, $0.0001 par value per share	530,000	$2.00	$1.06M
Sale	Common Stock, $0.0001 par value per share	530,000	$5.00	$2.65M
Conversion	Series Y Convertible Preferred Stock	900	$0.00	$0.00
Sale	Common Stock Purchase Warrants	1,300,000	$5.00	$6.50M
Sale	Common Stock Purchase Warrants	2,000,000	$5.24	$10.48M
Sale	Common Stock Purchase Warrants	1,700,000	$4.76	$8.09M
Conversion	Common Stock, $0.0001 par value per share	450,000	$2.00	$900K
Sale	Common Stock, $0.0001 par value per share	450,000	$5.00	$2.25M

Holdings After Transaction: Series Y Convertible Preferred Stock — 0 contracts (Indirect, Pyu Pyu Capital LLC); Common Stock Purchase Warrants — 2,000,000 contracts (Indirect, Pyu Pyu Capital LLC); Common Stock, $0.0001 par value per share — 0 shares (Indirect, Pyu Pyu Capital LLC)

Footnotes (4)

1. F1. Represents shares of common stock, par value $0.0001 per share ("Common Stock"), of the Issuer received upon conversion of the Issuer's Series Y Convertible Preferred Stock, par value $0.0001 per share, held by the Reporting Person at a conversion price equal to $2.00 per share.
2. F2. The reported securities are directly owned by Pyu Pyu Capital, LLC ("Pyu Pyu") and may be deemed to be beneficially owned by the Reporting Person as sole member of Pyu Pyu. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
3. F3. The shares of Common Stock were sold in private transactions at a price of $5.00 per share.
4. F4. The warrants were sold in private transactions at the specified price per warrant share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BiomX (PHGE) insider Yeganeh Reuven report in this Form 4?

Yeganeh Reuven reported indirect transactions through Pyu Pyu Capital LLC. The LLC converted Series Y Convertible Preferred Stock into Common Stock at $2.00 per share and then sold the resulting Common shares and Common Stock Purchase Warrants in private transactions.

How many BiomX (PHGE) common shares were sold in these transactions?

Pyu Pyu Capital LLC sold 980,000 BiomX common shares. It received 450,000 and 530,000 Common shares upon conversion of Series Y Convertible Preferred Stock and sold all of these shares in private transactions at a price of $5.00 per share.

What happened to the Series Y Convertible Preferred Stock in BiomX (PHGE)?

Series Y Convertible Preferred Stock held by Pyu Pyu Capital LLC was fully converted. A total of 1,960 preferred shares were converted into 450,000 and 530,000 Common shares at a conversion price of $2.00 per share, leaving no preferred shares reported afterward.

How many BiomX (PHGE) warrants were sold and at what prices?

Pyu Pyu Capital LLC sold 5,000,000 Common Stock Purchase Warrants. The warrants, exercisable at $1.00 per share, were sold in private transactions at prices between $4.76 and $5.24 per warrant share, with no warrants remaining reported.

Were the BiomX (PHGE) insider transactions open-market trades or private deals?

The Common Stock and warrants were sold in private transactions. Footnotes state that the Common shares were sold at $5.00 per share in private transactions, and the warrants were also sold privately at the specified price per warrant share.

Does Yeganeh Reuven directly own the BiomX (PHGE) securities involved?

The securities are directly owned by Pyu Pyu Capital LLC. They may be deemed beneficially owned by Yeganeh Reuven as sole member of the LLC, though he disclaims beneficial ownership except to the extent of his pecuniary interest in those securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 05:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yeganeh Reuven

(Last) (First) (Middle)

C/O BIOMX INC.

22 EINSTEIN ST., FLOOR 4

(Street)

NESS ZIONA 414003

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BiomX Inc. [ PHGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.0001 par value per share	03/16/2026		C(1)		450,000	A	$2(1)	450,000	I	Pyu Pyu Capital LLC(2)
Common Stock, $0.0001 par value per share	03/16/2026		S(3)		450,000	D	$5(3)	0	I	Pyu Pyu Capital LLC(2)
Common Stock, $0.0001 par value per share	03/17/2026		C(1)		530,000	A	$2(1)	530,000	I	Pyu Pyu Capital LLC(2)
Common Stock, $0.0001 par value per share	03/17/2026		S(3)		530,000	D	$5(3)	0	I	Pyu Pyu Capital LLC(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series Y Convertible Preferred Stock	$2(1)	03/16/2026		C(1)			900	01/13/2026	01/13/2027	Common Stock	450,000	$0(1)	1,060	I	Pyu Pyu Capital LLC(2)
Series Y Convertible Preferred Stock	$2(1)	03/17/2026		C(1)			1,060	01/13/2026	01/13/2027	Common Stock	530,000	$0(1)	0	I	Pyu Pyu Capital LLC(2)
Common Stock Purchase Warrants	$1	03/16/2026		S(4)			1,300,000	01/13/2026	01/13/2031	Common Stock	1,300,000	$5	2,000,000	I	Pyu Pyu Capital LLC(2)
Common Stock Purchase Warrants	$1	03/16/2026		S(4)			2,000,000	01/13/2026	01/13/2031	Common Stock	300,000	$5.24	1,700,000	I	Pyu Pyu Capital LLC(2)
Common Stock Purchase Warrants	$1	03/16/2026		S(4)			1,700,000	01/13/2026	01/13/2031	Common Stock	1,700,000	$4.76	0	I	Pyu Pyu Capital LLC(2)

Explanation of Responses:

1. Represents shares of common stock, par value $0.0001 per share ("Common Stock"), of the Issuer received upon conversion of the Issuer's Series Y Convertible Preferred Stock, par value $0.0001 per share, held by the Reporting Person at a conversion price equal to $2.00 per share.

2. The reported securities are directly owned by Pyu Pyu Capital, LLC ("Pyu Pyu") and may be deemed to be beneficially owned by the Reporting Person as sole member of Pyu Pyu. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

3. The shares of Common Stock were sold in private transactions at a price of $5.00 per share.

4. The warrants were sold in private transactions at the specified price per warrant share.

	/s/ Reuven Yeganeh	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)